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APJ is a seven transmembrane domain G-protein-coupled receptor that functions as a coreceptor for some primate
immunodeficiency virus strains. The in vivo significance of APJ coreceptor function remains to be elucidated, however, due
to the lack of an antibody that can be used to assess APJ expression, and because of the absence of an antibody or ligand
that can block APJ coreceptor activity. Therefore, we produced a specific monoclonal antibody (MAb 856) to APJ and found
that it detected this receptor in FACS, immunofluorescence, and immunohistochemistry studies. MAb 856 also recognized
APJ by Western blot, enabling us to determine that APJ is N-glycosylated. Using this antibody, we correlated APJ expression
with coreceptor activity and found that APJ had coreceptor function even at low levels of expression. However, we found that
APJ could not be detected by FACS analysis on cell lines commonly used to propagate primate lentiviruses, nor was it
expressed on human PBMC cultured under a variety of conditions. We also found that some viral envelope proteins could
mediate fusion with APJ-positive, CD4-negative cells, provided that CD4 was added in trans. These findings indicate that in
some situations APJ use could render primary cell types susceptible to virus infection, although we have not found any
evidence that this occurs. Finally, the peptide ligand for APJ, apelin-13, efficiently blocked APJ coreceptor activity. © 2000
Academic PressINTRODUCTION
Entry of primate immunodeficiency viruses into target
cells requires the interaction of the viral envelope protein
(Env) with cellular receptors (Berger et al., 1999; Doms
and Peiper, 1997; Moore et al., 1997). For primary HIV-1
strains, CD4 binding triggers conformational changes in
the gp120 subunit of Env that enables it to interact with
an appropriate coreceptor (Lapham et al., 1996; Trkola et
al., 1996; Wu et al., 1996). All HIV-1 strains use the
chemokine receptors CCR5 (R5 virus strains), CXCR4 (X4
virus strains), or both (R5X4 virus strains) as coreceptors
(reviewed in Doms and Moore, 1998). Coreceptor binding
is the probable triggering event that leads to membrane
fusion-inducing structural alterations in Env and subse-
quent virus entry. Thus, the differential use of CCR5 and
CXCR4 by virus strains coupled with the expression
pattern of these receptors largely governs HIV-1 tropism
at the level of entry.
Like HIV-1, SIV strains also use CD4 and coreceptors
to infect cells, though there are some important differ-
ences. First, nearly all SIV strains studied to date use
CCR5, whereas relatively few use CXCR4 (Edinger et al.,
1 To whom correspondence and reprint requests should be ad-
ressed at University of Pennsylvania, Department of Pathology and
aboratory Medicine, 806 Abramson Bldg., 34th and Civic Center Blvd.,
hiladelphia, PA 19104. Fax: (215) 573-2883. E-mail: doms@mail.
ed.upenn.edu.
4351999). Thus, differential use of CCR5 and CXCR4 cannot
by itself account for SIV cellular tropism. Second, SIV Env
proteins can bind directly to CCR5 in the absence of CD4
(Edinger et al., 1999; Martin et al., 1997). Third, a number
of primary SIV strains, particularly macrophage-tropic
and neurotropic isolates, exhibit a considerable degree
of CD4-independence, as they are able to infect CCR5-
positive cells that lack CD4 (Edinger et al., 1997a, 1999).
This has led us to the suggestion that CCR5 may have
been the primordial receptor for the primate lentiviruses
(Edinger et al., 1997a; Martin et al., 1997).
In addition to the major coreceptors, a number of
related chemokine and other seven transmembrane do-
main receptors can function as viral coreceptors (re-
viewed in Berger et al., 1999). These alternative corecep-
tors are only rarely used as efficiently as the major
coreceptors, they are used by smaller numbers of virus
strains, their use is not obviously related to virus tropism,
and their ability to support virus infection sometimes
requires levels of expression that are not attained in vivo.
However, use of alternative coreceptors could influence
viral tropism, particularly in specialized compartments
like the central nervous system and thymus. In addition,
use of alternative coreceptors could assume greater
importance in the face of effective small molecule inhib-
itors of CCR5 and CXCR4. It is therefore worthwhile to
study the alternative coreceptors, to identify which of the
approximately 15 identified to date might be most impor-
tant in vivo.
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436 PUFFER ET AL.To assess the potential relevance of an alternative
coreceptor, it is important to generate specific antibodies
so that the cell types in which the receptor is expressed
can be identified, and to determine whether expression
levels are sufficiently high to support virus infection. It is
also useful to obtain antibodies or ligands that can inhibit
coreceptor activity to determine whether the receptor
actually mediates infection in primary cell types. In this
report, we describe the development of the first mono-
clonal antibody directed to APJ, a seven transmembrane
domain receptor shown to function as a coreceptor for
some HIV-1 and SIV strains (Choe et al., 1998; Edinger et
l., 1998; Zhang et al., 1998). The expression of APJ and
he relationship between expression levels and corecep-
or function are described. In addition, we found that the
atural peptide ligand for APJ, apelin-13 (Tatemoto et al.,
998), efficiently blocked APJ coreceptor activity. These
eagents can be used to study APJ expression in vivo and
o determine whether APJ supports virus infection in a
iven cellular context.
RESULTS
eneration and characterization of a monoclonal
ntibody to APJ
We immunized mice with cells stably expressing APJ
o generate monoclonal antibodies (MAbs) to this HIV-1
oreceptor. Our previous attempts to generate antibod-
es to chemokine and related seven transmembrane do-
ain receptors using synthetic peptides have been
argely unsuccessful, whereas immunization of mice with
ells stably expressing the desired receptor preserves
he molecule’s native conformation and typically results
n the production of conformation-dependent MAbs (Lee
t al., 1999a; Sharron et al., 2000). Hybridomas were
creened against the stable APJ transfectants with the
arental NSO cell line serving as a negative control. A
ingle hybridoma was identified that was specific for the
PJ-positive cell type. After cloning, the IgG3 clone 72133
catalog no. MAb 856; R&D Systems, Minneapolis, MN)
as tested for the ability to recognize APJ on transiently
ransfected 293T cells by FACS. We found that MAb 856
ecognized 293T cells expressing APJ, but not cells
ransfected with the pCDNA3 vector alone or with plas-
ids expressing either CD4, CCR1, CCR2b, CCR3, CCR4,
CR5, CXCR1, CXCR2, CXCR4, GPR1, GPR15, ChemR1,
hemR23, STRL33, or CX3CR1/V28, confirming the spec-
ficity of this antibody (Fig. 1). Coexpression of CD4 with
PJ did not affect antibody reactivity (Fig. 1). Maximum
eactivity of MAb 856 for 293T cells transiently express-
ng APJ was obtained at a concentration of 20 mg/ml, and
maximum binding was obtained by 15 min.
We next investigated whether MAb 856 could be used
in other experimental formats. We found that MAb 856
recognized APJ by Western blot, indicating that, unlike
most MAbs we have generated against seven transmem-brane domain receptors, MAb 856 most likely recognizes
a conformation-independent, linear determinant (Fig. 2).
APJ could be resolved by SDS–PAGE only in the absence
of boiling. If samples were boiled, the bulk of the APJ
aggregated and failed to enter the separating gel. West-
ern blot analysis of the resolved APJ protein detected
three discrete bands, suggesting that the protein was
posttranslationally modified. Because of the spacing of
the bands, the fact that APJ contains two potential N-
linked glycosylation sites, and that other HIV coreceptors
contain N-linked carbohydrates (Berson et al., 1996), we
felt that this banding pattern was most consistent with
carbohydrate modifications. Indeed, when cells express-
ing APJ were treated with tunicamycin to inhibit N-linked
glycosylation, only a single band was detected which
comigrated with the most quickly migrating band ob-
served in the absence of tunicamycin (Fig. 2). Therefore,
we conclude that APJ is N-glycosylated. The presence of
three bands could be consistent with incomplete glyco-
sylation (perhaps as a consequence of overexpression)
in which zero, one, or two N-linked sites are used. Alter-
natively, carbohydrate processing in the Golgi could ac-
FIG. 1. Characterization of MAb 856. 293T cells were transfected
with CD4 and/or the designated chemokine/orphan receptor expres-
sion plasmid. Cells were lifted off the plate with PBS, stained with
MA856 as described under Materials and Methods, and analyzed by
FACS.count for some of the mobility differences.
MAb 856 recognized APJ transfectants by immunoflu-
437IN VIVO SIGNIFICANCE OF APJ CORECEPTOR FUNCTIONorescence following paraformaldehyde treatment, giving
a typical cell surface staining pattern (Fig. 3B). Staining of
293T cells transfected with pCDNA3 vector demon-
strated background levels (Fig. 3A). To determine
whether MAb 856 could be used for immunohistochem-
ical analysis of paraffin-embedded sections, we stained
sections of human cerebellum (Fig. 3D) since APJ mes-
sage has been reported to be abundant in the CNS
(O’Dowd et al., 1993). We found that MAb 856 recognized
a subset of cells in these sections, including pyramidal
neurons in the hippocampus (data not shown). Thus,
MAb 856 can be used to characterize APJ expression in
tissue sections. Confirmation of the staining pattern ob-
tained with MAb 856 by an additional technique such as
in situ hybridization for APJ message should be consid-
ered until additional antibodies to APJ are obtained.
APJ expression on cell lines and primary human
PBMCs
We used MAb 856 to stain a number of cell lines
commonly used for HIV and SIV infectivity studies be-
cause of its potential to function as a viral coreceptor. We
FIG. 2. APJ is N-glycosylated. 293T cells transfected with GFP-
(Mock), CCR5, or APJ constructs were cultured overnight in the pres-
ence (lanes 3 and 5) or absence (lanes 1, 2, 4, and 6–9) of tunicamycin.
Lysates were prepared as described under Materials and Methods;
approximately 30,000 cell equivalents of each sample were mixed with
sample buffer and heated to either 37°C (lanes 1–5), 55°C (lanes 6 and
7), or boiled (lanes 8 and 9). Proteins were resolved by SDS–PAGE,
transferred to PVDF membrane, and detected by MAb 856.did not detect APJ expression on CEMX174, CEMss,
clone 8, U937, HUT-78, U87, THP-1, PM-1, Jurkat, or C8166cells by FACS analysis. We previously failed to identify
APJ mRNA in these cells as judged by RT-PCR analysis,
with the exception of C8166 cells in which an APJ-spe-
cific reaction product was detected (Edinger et al., 1998).
Therefore, we conclude that these commonly used cell
lines either do not express APJ or express less than 1000
copies of this receptor per cell, which is the approximate
limit of APJ detection using MAb 856 (not shown) and a
quantitative FACS protocol (Lee et al., 1999b).
Alternative HIV-1 coreceptors that are expressed on
CD4-positive cell types in vivo are more likely to be
relevant for HIV tropism and pathogenesis than recep-
tors that are not. Previously, we failed to detect APJ-
specific transcripts in adult human microglia, monocyte-
derived macrophages, and PBMCs cultured under a va-
riety of conditions (Edinger et al., 1998). However, an
independent report demonstrated the presence of APJ
cDNA in human PBMC activated with PHA plus IL-2
(Choe et al., 1998). We used MAb 856 to stain freshly
isolated human PBMC as well as PBMC activated with
IL-2 or a combination of PHA and IL-2. While CXCR4
expression was readily detected on both CD4-positive
and -negative PBMC, APJ was not detected on cells
grown under any condition (Fig. 4). These results, cou-
pled with our previous RT-PCR analyses, argue that APJ
is not expressed on CD4-positive T-cells, at least not at
levels that can be detected by MAb 856.
Antiviral activity of the APJ ligand apelin
An endogenous 36-amino-acid-long peptide ligand
for APJ, termed apelin, has been identified and iso-
lated from bovine stomach extracts. When apelin was
added to CHO cells stably expressing APJ, it resulted
in an increase in extracellular acidification (Tatemoto
et al., 1998). In addition, a 13-amino-acid-long C-termi-
nal fragment of apelin, apelin-13, exhibited increased
activity (Tatemoto et al., 1998). To determine whether
apelin-13 could inhibit APJ coreceptor function, we
synthesized this peptide. Addition of apelin-13 to hu-
man 293T cells expressing APJ that had been loaded
with the calcium-sensitive dye Fura-2 resulted in an
increased fluorescent signal, consistent with the in-
creases in intracellular calcium observed after ligand
binding to many other seven transmembrane domain
receptors (Fig. 5). This confirmed that our synthetic
apelin-13 was biologically active and demonstrated
that apelin induces calcium signaling in APJ-express-
ing cells. Apelin-13-induced APJ receptor signaling
could not be inhibited by preincubating APJ-express-
ing cells with MAb 856, indicating that this antibody
does not inhibit ligand binding. We also assessed the
ability of apelin-13 to induce a calcium flux in human
PBMC, but failed to observe a response. In contrast,
the addition of RANTES led to a readily observed





438 PUFFER ET AL.tional evidence that APJ is not expressed in human
PBMC.
Having confirmed that the synthetic apelin-13 was
biologically active, we asked whether it could inhibit APJ
coreceptor activity. Because relatively few virus strains
can use APJ to infect cells efficiently, we used a cell–cell
fusion assay so that APJ coreceptor activity for several
Env proteins could be easily monitored (Edinger et al.,
1998). As shown in Fig. 6, quail QT6 cells expressing
CD4 and APJ supported fusion by cells expressing either
the SIVmac316, HIV-1 89.6, or HIV-1 HXB Env proteins.
Apelin-13 blocked APJ-dependent cell–cell fusion in a
concentration-dependent manner (Fig. 6). By contrast,
apelin-13 did not inhibit SIVmac316 or HIV-1 89.6 use of
CCR5, nor did it inhibit HIV-1 89.6 or HXB use of CXCR4
(Fig. 6), confirming its specificity for APJ. The apelin-36
full-length peptide also blocked Env fusion via the APJ
receptor (data not shown). Unlike apelin-13, MAb 856 did
not block APJ coreceptor activity under any condition
tested (data not shown). These results are in agreement
with a recent study by Zou et al. (2000), who showed that
FIG. 3. MAb 856 detects APJ by immunofluorescence and immunope
MAb 856 (B) and processed for immunofluorescence as described und
mouse IgG (C) or MAb 856 (D) and processed for immunoperoxidasepelin peptides of various lengths could block infection
f APJ-positive cells by either HIV-1 or HIV-2.APJ coreceptor activity as a function of receptor
expression levels
Generally, for a coreceptor to be relevant in vivo, it
must be expressed on CD4-positive cells and it must be
expressed at levels sufficiently high to support virus
infection. Some alternative coreceptors, such as STRL33,
support virus infection at nonphysiological expression
levels, at least for some virus strains (Sharron et al.,
2000). To determine the levels of APJ surface expression
required for coreceptor activity, we transiently trans-
fected human 293T cells with a constant amount of a
CD4 expression plasmid and serial dilutions of plasmids
expressing APJ, CCR5, or CXCR4. The next day, the ability
of these cells to support cell–cell fusion by the HIV-1
89.6, HXB, and SIVmac316 Env proteins was tested (Figs.
7B, 7C, and 7D, respectively). We confirmed by FACS
analysis that receptor expression was indeed related to
the amount of plasmid used (Fig. 7A). Consistent with
previous work, we found that, whereas coreceptor activ-
ity diminished as receptor levels decreased, both CCR5
and CXCR4 supported detectable levels of cell–cell fu-
e staining. Transfected 293T cells were stained with mouse IgG (A) or
erials and Methods. Human cerebellum sections were incubated with
g.roxidassion, even at very low levels of receptor expression (Fig.


































439IN VIVO SIGNIFICANCE OF APJ CORECEPTOR FUNCTIONpattern: there was not a threshold level below which
coreceptor activity was lost (Figs. 7B, 7C, and 7D). There-
fore, we conclude that APJ can function as an HIV-1
coreceptor, even when expressed at low levels.
Rescue of APJ coreceptor activity by soluble CD4
Although APJ could function as a coreceptor at expres-
sion levels likely to be found in vivo, we have not de-
tected APJ expression on CD4-positive cell types. How-
ever, APJ could still prove to be a relevant coreceptor in
ivo under some circumstances. Specifically, a number
f primary SIV and HIV-2 strains have been identified that
an infect cells in a CD4-independent fashion (Edinger et
al., 1997a; Reeves et al., 1999). In addition, Goldsmith and
olleagues showed that primary fetal human astrocytes,
hich are CD4-negative but do express CXCR4, could be
FIG. 4. APJ is not expressed on human PBMC. Human PBMC were
cultured with IL-2 or IL-2 with PHA for 4 days prior to staining with
MAbs specific for the APJ, CXCR4, or CD4, and FACS analysis. APJ or
CXCR4 expression is shown on CD41 or CD81 T cells as indicated.
he dotted line represents the staining obtained with the isotype-
atched control antibody; the solid line indicates the specific antibody.nfected by X4 virus strains, provided that CD4 was
upplied in trans (Speck et al., 1999). This could be
w
3ccomplished either by the addition of soluble CD4 or by
D4-positive cell types. To determine whether APJ-pos-
tive, CD4-negative cells could exhibit coreceptor activity
hen CD4 is provided in trans, we used the cell–cell
usion assay. Cells expressing the HIV-1 89.6, HIV-1 HXB,
r SIVmac316 Env proteins did not fuse with cells ex-
ressing APJ alone (Fig. 8). Addition of sCD4, however,
nabled cells expressing the HIV-1 89.6 and HXB Env
roteins, but not cells expressing SIVmac316, to fuse
ith APJ-positive cells. Thus, as has been observed for
XCR4 and CCR5, APJ coreceptor activity can be sup-
orted in some circumstances by CD4 added in trans.
DISCUSSION
The discovery of the major primate immunodeficiency
irus coreceptors has greatly expanded our understand-
ng of viral tropism and pathogenesis and for defining
ew drug targets. While the importance of CCR5 and
XCR4 for HIV-1 and CCR5 for SIV is clear, the in vivo
elevance of the approximately 15 alternative corecep-
ors identified to date is not. Alternative coreceptors have
een discovered using a variety of experimental ap-
roaches, but in all cases they have been defined as
eing competent to mediate infection of one or more
FIG. 5. Apelin-13 induces an increase in intracellular calcium. 293T
cells were transfected with APJ, loaded with FURA-2 calcium indicator
dye, and resuspended in D-PBS with Ca21 and Mg21. The cells were
hen placed in a cuvette at 37°C, and fluorescence detected in re-
ponse to apelin, and thrombin receptor agonist (TAP) peptides. TAP
as used as a positive control to confirm that FURA-2-loaded cells
ere both viable and responsive. Emissions were monitored at 340 and









are shown. The results from the other three experiments were similar.
one of three representative experiments are shown. The results from the othe
values varied between experiments because transient transfections were em
440 PUFFER ET AL.virus strains when expressed in a cell line along with
CD4. In at least some cases, alternative coreceptors
share considerable sequence homology with CCR5, or
contain structural motifs that have been shown to be
important for coreceptor function (Choe et al., 1998;
Dragic et al., 1998; Farzan et al., 1998). APJ falls into the
latter category, sharing an acidic, tyrosine-rich motif
found in the N-terminal domains of many coreceptors,
including CCR5 and CXCR4, even though the receptor
shares greater overall similarity with the angiotensin
receptor family (Choe et al., 1998; O’Dowd et al., 1993).
Given these structural similarities and the sequence vari-
ability characteristic of the V1/2 and V3 regions of Env
that are largely responsible for coreceptor choice (re-
viewed in Hoffman and Doms, 1999), it is perhaps not
surprising that molecules other than CCR5 and CXCR4
can mediate entry for some virus strains, particularly
when the receptors are overexpressed. The real ques-
tion is whether any of these receptors are currently
relevant in vivo, or could become relevant if small mole-
cule receptor antagonists provide selective pressure for
viral evolution.
For an alternative receptor to be generally relevant in
vivo, it needs to be expressed in CD4-positive cells at
levels sufficient to mediate virus infection. Receptor ex-
target cells were transfected with T7-luciferase, CD4, and coreceptor
xamined by FACS for coreceptor expression levels (A) or mixed with
tively), and fusion activity was assayed by luciferase activity. Data fromFIG. 6. Inhibition of APJ coreceptor activity by apelin-13. QT6 cells
xpressing CD4 and the indicated coreceptor were incubated with
pelin-13 for 15 min prior to addition of effector cells expressing the
ndicated Env protein. Targets and effectors were mixed and incubated
or 6–7 h at 37°C, then cells were lysed with 0.1% Triton/PBS and
ysates were assayed for luciferase activity. Fusion for each envelope
n the absence of apelin was normalized to100% to make it possible to
ompare envelopes with widely different fusion activities for this alter-
ative coreceptor. Data from one of four representative experimentsFIG. 7. APJ expression levels and coreceptor activity. Duplicate wells of QT6
at the designated concentrations. At 24 h posttransfection cells were either e

































































441IN VIVO SIGNIFICANCE OF APJ CORECEPTOR FUNCTIONpression levels clearly influence coreceptor activity. In
general, coreceptor activity falls as receptor expression
levels decrease, though the major coreceptors (CCR5
and CXCR4) can support some degree of infection even
at low levels of expression (Edinger et al., 1999; Kozak et
l., 1997; Kuhmann et al., 2000; Platt et al., 1998; Sharron
t al., 2000). This may not be true for some alternative
oreceptors, which may function only at very high levels
f receptor expression. In the case of STRL33, some
irus strains can use this receptor for infection only at
evels of expression that far exceed levels that are found
n vivo (Sharron et al., 2000). Whether this is true for
dditional coreceptors has not yet been determined,
ften because specific antibodies are not available. By
eveloping a MAb specific for APJ, we were able to
etermine that APJ, like the major coreceptors, functions
ven at very low levels of expression. Thus, levels of APJ
ound in vivo are likely to be sufficient for coreceptor
ctivity, provided that CD4 is present, since we have not
bserved CD4-independent use of APJ by any HIV-1 or
IV strain examined to date.
APJ expression has been studied through analysis of
PJ message, often by RT-PCR, with conflicting results
ith regards to expression of APJ in CD4-positive pri-
ary cell types (Choe et al., 1998; Edinger et al., 1998).
ifferences observed could be the result of either donor
ariability or the highly sensitive nature of the RT-PCR
echnique. Using MAb 856, we found that APJ was not
xpressed at detectable levels in numerous cell lines or
n CD4-positive T-cells from four donors, cultured under
FIG. 8. Effects of CD4 provided in trans on APJ coreceptor activity. A
fusion assay was performed using QT6 target cells transfected with APJ
and T7 luciferase in the presence or absence of CD4 expression vector.
At 24 h posttransfection, effector cells expressing the designated Env
and T7 polymerase were added to the targets and the media was
supplemented with soluble CD4 (sCD4). Approximately 6–7 h after
mixing, cells were lysed and assayed for luciferase activity. Data from
one experiment of three replicates are shown. All values were normal-
ized to levels of fusion detected when effectors were mixed with target
cells transfected with APJ and CD4. mCD4 indicates cellularly ex-
pressed, membrane-bound CD4.variety of conditions. In addition, apelin-13 did not
nduce a detectable calcium response in human PBMC,roviding additional evidence that APJ is either not ex-
ressed in human PBMC or is present at very low levels.
hese findings, coupled with our inability to detect APJ
essage in monocyte-derived macrophages or micro-
lia (Edinger et al., 1998), lead us to conclude that APJ is
ot likely to be of major importance as a coreceptor in
ivo. This is in contrast to another alternative coreceptor
hat we have studied in detail, STRL33. We found that
TRL33 was expressed in some CD4-positive T-cells,
hat it was expressed at levels sufficient to support
nfection for some viruses, and we identified one primary
IV-1 strain that could infect some CD4-positive T-cells
ndependently of CCR5 and CXCR4 by using STRL33
Sharron et al., 2000). Although it is possible that MAb
56 may not detect all conformations of APJ, the negative
ACS results coupled with our inability to detect APJ-
pecific message argues strongly that this alternative
oreceptor is not expressed in the most important cell
ypes for HIV-1 infection in vivo. MAb 856 and apelin-13,
owever, will be important in elucidating the normal
unction of APJ.
Though APJ is not likely to be a relevant HIV-1 core-
eptor in vivo, it could potentially support virus infection
n specialized contexts. APJ message is relatively abun-
ant in the CNS, an important site of HIV-1 infection
O’Dowd et al., 1993). Indeed, we found APJ expression in
subset of pyramidal neurons using MAb 856 and im-
unoperoxidase staining. The ability of MAb 856 to de-
ect APJ in this format will make it possible to carefully
tudy APJ expression in solid tissues. There is reason-
ble evidence that CD4-negative cell types in the CNS
an be infected by HIV-1, though this is not a universal
inding (reviewed in Kolson et al., 1998). When infection
f CD4-negative cell types is observed, the efficiency of
his process is not known nor are the mechanisms of
irus entry. Goldsmith and coworkers (Speck et al., 1999)
howed that some HIV-1 strains could infect CD4-nega-
ive human astrocytes in vitro, provided CD4-positive
cells were also present. This, and experiments in which
soluble CD4 could render some CD4-negative cells sus-
ceptible to infection, provides at least one mechanism for
CD4-independent infection (Schenten et al., 1999; Speck
et al., 1999). It will be difficult to determine whether this
occurs in vivo, though if neurotropic virus strains in
general are better able to infect cells via this pathway,
then the case for this infectious entry pathway being
relevant in vivo becomes stronger. In the case of SIV,
many virus strains exhibit at least some degree of CD4-
independence, but this is almost invariably mediated by
CCR5 (reviewed in Edinger et al., 1999). Thus, we con-
sider CD4-independent, APJ-dependent SIV infection to
be an unlikely event. Finally, engagement of coreceptors
by the viral Env protein could potentially trigger signaling
events that could impact cell health and viability. This,
again, is a somewhat controversial area and one that is













442 PUFFER ET AL.worthwhile to determine whether APJ signaling induced
by apelin or Env has any physiological consequences in
primary cells derived from the CNS. The generation of
MAb 856 and the ability of the APJ ligand apelin-13 to
induce an increase in intracellular calcium and block
coreceptor activity will make it possible to study these
questions, and point out the importance of developing
antibodies and identifying natural ligands for other viral
coreceptors, whether real or an in vitro artifact.
MATERIALS AND METHODS
Antibodies
The antibodies used in this study included FITC-con-
jugated anti-CD4, tricolor-conjugated anti-CD8, and goat
anti-mouse F(ab9)2 IgG (H 1 L) R-phycoerythrin conju-
ated (all from Caltag Laboratories, Burlingame, CA).
ntibodies from R&D Systems included anti-human
XCR4 MAb173 and anti-APJ MAb 856. Other antibodies
ncluded anti-CXCR4 MAb 12G5 (Endres et al., 1996) and
nti-CCR5 MAb 2D7 (Pharmingen, San Diego, CA). MAb
56 (mouse anti APJ clone 72133; R&D Systems) was
ade by immunizing Balb/c mice using syngenic mouse
yeloma (NSO) cells stably expressing the full-length
uman APJ sequence (O’Dowd et al., 1993).
estern blot analysis
293T cells transfected with a pCDNA3 APJ expression
lasmid were cultured overnight in the presence or ab-
ence of 5 mg/ml tunicamycin. At 24 h posttransfection,
cells were lysed in RIPA buffer (1% deoxycholate, 1%
Triton X-100, 150 mM NaCl, 250 mM Tris, pH 8.0) and the
nuclear fraction was removed by low-speed centrifuga-
tion. SDS–PAGE (63) sample buffer containing reducing
agent was added and lysates were heated to 37, 55, or
95°C immediately prior to resolution of proteins on 10%
acrylamide gels. Proteins were transferred to PVDF
membranes (Millipore, Bedford, MA) and nonspecific
protein binding was blocked with blotto for 1 h. MAb 856
was added at a 1:1000 dilution for 1 h, then the blot was
washed several times with 0.2% Triton X-100 in PBS.
Anti-mouse HRP conjugate (Promega, Madison, WI) was
added at a 1:10,000 dilution for 1 h, washing was re-
peated, and proteins detected with Supersignal (Pierce,
Rockford, IL).
Cell–cell fusion assay
This assay has been described previously (Rucker et
al., 1997). Briefly, effector 293T or QT6 cells were infected
with vaccinia virus expressing T7 polymerase (vTF1.1)
(Alexander et al., 1992) and with a vaccinia expressing
the HIV-1 89.6 (vBD3) (Doranz et al., 1996), SIVmac316
(vCB75) (Edinger et al., 1997b), or HIV-1 HXB (vPE16) (Earl
et al., 1991) Env proteins. Target QT6 quail cells were
transfected with plasmids expressing CD4, coreceptor,
g
aand T7-luciferase. At 24 h postinfection or transfection
effector cells were added to the target cells and fusion
quantitated 7 h postmixing by lysing cells with 0.05%
Triton X-100 in PBS and measuring luciferase activity.
Ligand blocking or soluble CD4 studies were performed
by adding ligand or CD4 to target cells approximately 15
min prior to addition of effector cells.
Calcium mobilization assay
Calcium signaling response was measured in 293T
cells transfected with plasmids expressing CCR5 or APJ,
or empty vector via calcium phosphate. At 24 h post-
transfection approximately 1 3 106 cells were loaded
with FURA2-AM (Molecular Probes, Eugene, OR) for 1 h,
then washed with PBS without Mg21 or Ca21 and gently
lifted from the plate by pipetting. Cells were pelleted and
resuspended in Dulbecco’s PBS with Mg21 and Ca21
(BioWhittaker, Walkersville, MD) at 2 3 106 cells per ml,
and fluorescence was measured with an Aminco-Bow-
man luminescence spectrometer in a stirring cuvette.
Excitation and emission were monitored at 340 and 380
nm and extracellular calcium concentration was calcu-
lated as described (Grynkiewicz et al., 1985). Apelin-13
peptide was added at 3 mg/ml and thrombin receptor
agonist peptide (TAP) was added to a concentration of 27
mM following addition of ligand as a control, to confirm
that cells were permissive for induction of calcium sig-
naling.
Immunohistochemistry
Paraffin-embedded tissue was dehydrated in graded
alcohol baths and then deparaffinized in xylene. After
rehydration the sections were quenched for 20 min in
0.8% hydrogen peroxide in methanol. Sections were then
incubated in 2% normal horse serum (Vector Laborato-
ries, Burlingame, CA) followed by an overnight incuba-
tion at 4°C in primary antibody. The sections were
washed and incubated with a biotinylated secondary
antibody (1:750) (Vector Laboratories) followed by incu-
bation with avidin-biotin-peroxidase complex (Vector
Laboratories). After washing, the slides were developed
with 39,39-diaminobenzidene to give a brown reaction
product (Sigma, St. Louis, MO) and then dehydrated and
mounted with Cytoseal (VWR Scientific, Boston, MA).
Immunofluorescence staining
All cells were fixed in 4% paraformaldehyde/PBS/4%
sucrose for 20 min at 4°C. Permeabilization was carried
out by treating the fixed samples with methanol (220°C)
for 10 min at 4°C and then 0.2% Triton X-100 for 10 min at
4°C. Blocking was carried out in 10% goat serum/PBS for
30 min at room temperature (RT). The antibody was
reconstituted to a final concentration of 9 mg/ml in 10%oat serum/PBS and incubated with the samples for 1 h




















443IN VIVO SIGNIFICANCE OF APJ CORECEPTOR FUNCTIONconcentration as the APJ antibody. The coverslips were
washed with PBS three times and then incubated for 1 h
at RT with goat anti-mouse Alexa FITC at a final concen-
tration of 4 mg/ml. The coverslips were washed with PBS
hree times and then mounted in Fluoromount (Southern
iotechnology Associates, Birmingham, AL), sealed, and
hotographed. Images were captured using a Nikon
clipse E600 microscope attached to a Nikon camera
nd the software package Phase 3 Imaging Systems,
sing a 40 3 10 non-oil-immersion lens.
FACS analysis
Stimulated PBLs cultured for 4 days with either IL-2 or
IL-2/PHA were incubated for 30 min on ice in FACS-
staining buffer (PBS, 3% FBS, 0.05% sodium azide) with
10 mg/ml of the designated antibody. Cells were washed
n 1 mL FACS-staining buffer, then incubated with the
ecommended dilution of anti-mouse PE antibody. Wash-
ng was repeated and cells were incubated with recom-
ended concentrations of the CD4 and CD8 antibodies.
ells were washed again and fixed in 1% paraformalde-
yde. Fluorescence staining was analyzed on a FACScan
Becton Dickinson, San Jose, CA) with the Cellquest
oftware package.
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